研究单位：[1]Sunshine Lake Pharma Co., Ltd.[2]Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology Wuhan, Hubei, China, 430022[3]Tongji Hospital Affiliated to Tongji Medical College of Huazhong University Science & Technology Wuhan, Hubei, China, 430030[4]Renmin Hospital of Wuhan University Wuhan, Hubei, China, 430060[5]Xiangyan Hospital, Central South University Changsha, Hunan, China, 410008[6]The Second Hospital of Nanjing Nanjing, Jiangsu, China, 210003[7]The First Affiliated Hospital of NanChang University Nanchang, Jiangxi, China, 330006[8]The First Hospital of Jilin University Chang Chun, Jilin, China, 130021[9]Tangdu Hospital Xi'an, Shanxi, China, 710038[10]West China Hospital, Sichuan University Chengdu, Sichuan, China, 610041[11]Peking University First Hospital Beijing, Beijing, China, 100034[12]Peking University People's Hospital Beijing, Beijing, China, 100044[13]Beijing YouAn Hospital,Capital Medical University Beijing, Beijing, China, 100069[14]The First Hospital of Lanzhou University Lanzhou, Gansu, China, 730000[15]Guangzhou Eighth People's Hospital Guangzhou, Guangdong, China, 510060[16]Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China, 510515[17]Hainan General Hospital Haikou, Hainan, China, 570311[18]The Third Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050051
The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection
